Wet AMD

Optical coherence tomography angiography (OCT-A) is a new, non-invasive imaging technique used to evaluate retinal and choroidal microvasculature. This cross-sectional study, published in the Annals of Medicine and Surgery, sought to determine OCT-A’s diagnostic accuracy in assessing the morphological features and clinical activity of macular neovascularization (MNV) in wet age-related macular degeneration (AMD).  The researchers’ study...

Patients with wet age-related macular degeneration (AMD) require ongoing anti-VEGF treatments, which must be administered at an optimal frequency for their condition. This study, published in Translational Vision Science & Technology, sought to provide a probabilistic forecast for anti-VEGF treatment frequency using volumetric spectral domain-optical coherence tomography (SD-OCT).  The researchers used SD-OCT volume scans in conjunction...

Although the clinical efficacy of anti-VEGF treatments for wet age-related macular degeneration has been established, real-life results may differ, particularly due to the difficulty of managing treatment over time. This retrospective cohort study, published in BMC Ophthalmology, describes and analyzes real-life data from patients treated with anti-VEGFs, and compares them to data from previous clinical trials...

The gold standard treatment for wet age-related macular degeneration (AMD) involves repeated administration of anti-VEGF intravitreal injections. Unfortunately, due to the ongoing COVID-19 pandemic, many patients worldwide have been unable to receive treatment due to lockdowns or other measures and restrictions. This study, published in Ophthalmology and Therapy, focuses on the effects of delayed treatment of...

Targeting VEGF and the VEGFR2 receptor are promising treatment modalities for wet age-related macular degeneration. This study, published in Investigative Ophthalmology & Visual Science, used the peptide KAI to interfere with VEGFR2 trafficking. The study sought to determine how efficacious this peptide is in the mouse model of choroidal neovascularization. Surface plasmon resonance was used to...

Both ranibizumab and aflibercept are used as anti-VEGF agents to treat wet AMD. This cross-sectional study, published in Graefe’s Archive for Clinical and Experimental Ophthalmology, evaluated wet AMD outcomes after 12 months in patients who switched from ranibizumab to aflibercept, regardless of previous drug response.  The researchers tested visual acuity, treatment frequency, and retinal morphology after...

Because hypertension and wet age-related macular degeneration (AMD) are both found in elderly patients, their relationship is unclear. This study, published in Acta Ophthalmologica, attempted to analyze the association between hypertension and wet AMD and how their co-occurrence may impact wet AMD treatment strategies.  The study relied on electronic healthcare records from 2002 to 2019. A...

Anti-VEGF therapy is currently considered the most effective way to treat wet AMD but is highly burdensome for patients. Chitinase-3-like-1 (YKL-40) could serve as an alternative target for wet AMD treatment, as it has been shown to promote microangiogenesis and inflammation.  This study, published in FEBS Open Bio, investigated the role of YKL-40 in wet AMD....

The standard treatment for patients with wet AMD is antivascular endothelial growth factor therapy. Although effective, this treatment’s need for costly lifelong injections makes it less than ideal. Gene therapy for wet AMD can allow for the sustained delivery of antiangiogenic proteins, resulting in potentially less burdensome treatment for patients. This study, published in The British...